



Gesellschaft Spanischer  
Wissenschaftler in der  
Bundesrepublik Deutschland

# A Taste of Spanish Research

## 2021 CERFA Cancer Symposium

### Monday 17<sup>th</sup> May

**8:45** Opening

**Session I.** Chair: Samuel Peña-Llopis. DTKT Junior Group Leader. *Translational Genomics in Solid Tumors. University Hospital Essen. Germany*

**9:00** Marisol Soengas. *Melanoma Group, CNIO, Madrid.*

“Managing and targeting premetastatic niches: applications to immunotherapy”

**9:30** Juan Rodriguez-Vita. *Tumor-Stroma Communication. CIPF, Valencia and DKFZ, Heidelberg.*

“Hyaluronic acid is a master regulator of tumour stroma”

**10:00** Ana Janic. *Cancer Biology. UPF, Barcelona.*

“Identification of the critical p53 tumor suppressor mechanisms”

**10:30** Laura Soucek. *Mouse models of Cancer Therapies Group. VHIO, Barcelona.*

“Attacking an “Undruggable” target to combat cancer”

**11:00** Selected Flash Talks

- Lena Wiedmann. “*HAPLN1 is a driver for tumor cell hyperplasticity and CAF-dependent immune-modulation in PDAC*”. German Cancer Research Center (DKFZ), Germany.
- Mónica Martínez Fernández. “*Activation of retrotransposon LINE1 is an early event in Head and Neck Squamous Cell Carcinoma*”. Galicia Sur Health Research Institute (IIGS), Spain.
- Lukas Klein. “*Inflammatory Macrophages Promote Basal-like Subtype Identity via Enhancer Reprogramming in Pancreatic Cancer*”. University medical Center Göttingen, Germany
- Elisa Donato. “*Identification of genetic, epigenetic and cellular alterations responsible for distinct clinical outcomes of DNMT3A mutant AML*”. German Cancer Research Center (DKFZ), Germany.
- Rafael Carretero Coca. “*Enhancement of anti-tumor T-cell immunity by means of an oral small molecule targeting the intracellular immune checkpoint MAP4K1*”. German Cancer Research Center (DKFZ), Germany.

**11:30** Coffee/lunch break with poster viewing in Gather



FUNDACIÓN  
RAMÓN ARECES

**aseica**  
investigando  
en cáncer

**Session II.** Chair: Pilar Acedo. Junior Group Leader. *Institute for Liver & Digestive Health. Division of Medicine. University College London. UK*

**12:30** Roger Gomis. *Growth Control and Cancer Metastasis. IRB, Barcelona.*  
“Metastasis latency in breast cancer”

**13:00** María M Caffarel. *Breast Cancer Group. Biodonostia Health Research Institute, Donostia-San Sebastián.*  
“Stromal Oncostatin M axis promotes breast cancer progression and tumour-promoting inflammation”

**13:30** Toni Celià-Terrassa. *Cancer Stem Cells and Metastasis Dynamics. IMIM, Barcelona.*  
“Tumor plasticity implications in breast cancer immunity”

**14:00** Concluding remarks of the day

---

## Tuesday 18<sup>th</sup> May

**Session III** Chair: TBD

**9:00** Manuel Valiente. *Brain Metastasis Group. CNIO, Madrid.*  
“Strategies to challenge brain metastasis lethality in mice and human”

**9:30** Sònia Guedan. *Hematopoietic Progenitor Cell Transplantation. IDIBAPS, Barcelona.*  
“CAR-T cell therapy: Engineering immune cells to fight cancer”

**10:00** Arkaitz Carracedo. *Cancer Cell Signalling and Metabolism Group. CIC bioGUNE, Bizkaia.*  
“Metabolic and signaling drivers of prostate cancer progression”

**10:30 – 12:00** *Poster viewing + coffee/lunch time*

**12:00 – 12:15** *Poster evaluation*

**Session IV** Chair: TBD

**12:20** Maite Huarte. *Long noncoding RNA and Gene Regulation in Cancer. CIMA, Navarra.*  
“Chromatin-related functions of lncRNAs in the regulation of cancer pathways”

**12:50** María Abad. *Cellular Plasticity and Cancer Group. VHIO, Barcelona.*  
“Mining the cancer microproteome for novel drivers of cancer cell plasticity”

**13:20** *Poster prize and concluding remarks*



FUNDACIÓN  
RAMÓN ARECES

**aseica**  
investigando  
en cáncer

## Posters

#	Title	Presenter	Affiliation
<b>P01</b>	<i>Essential role of endothelial Notch activation in the re-education of tumor associated macrophages</i>	Elisenda Alsina-Sanchis	German Cancer Research Center (DKFZ), Germany
<b>P02</b>	<i>HAPLN1 is a driver for tumor cell hyperplasticity and CAF-dependent immune-modulation in PDAC</i>	Lena Wiedmann	German Cancer Research Center (DKFZ), Germany
<b>P03</b>	<i>L1CAM reduces tumorigenicity, stemness and fibrosis in pancreatic ductal adenocarcinoma</i>	Donatella Delle Cave	Institute of Genetics and Biophysics "A. Buzzati Traverso" (IGB-ABT), Italy
<b>P04</b>	<i>Long non-coding RNA FAM30A as a novel regulator of leukemic stem cell fate in acute myeloid leukemia</i>	Jaime Calvo Sánchez	Martin-Luther University Halle-Wittenberg, Germany
<b>P05</b>	<i>Activation of retrotransposon line1 is an early event in head and neck squamous cell carcinoma</i>	Monica Martinez Fernandez	<b>Galicia Sur Health Research Institute</b> (IISGS), Spain
<b>P06</b>	<i>mRNA vaccination platform for cancer therapeutics based on proprietary polymeric nanoparticles platform</i>	Cristina Fornaguera	Institut Químic de Sarrià (IQS), Universitat Ramon Llull (URL), Spain
<b>P07</b>	<i>Multimodal clinical mass Spectrometry to TArget treatment ReSistance</i>	Álvaro Fernández Ochoa	Max Delbrück Center for Molecular Medicine, Germany
<b>P08</b>	<i>ERK2 drives MYC expression acting as a kinase-independent anchor for CDK9 at the MYC promoter</i>	Marta Morante Ezquerro	IBBTEC, Spain
<b>P09</b>	<i>Characterization of the role of innate lymphoid cells in nonalcoholic fatty liver disease</i>	Xin Li	German Cancer Research Center (DKFZ), Germany
<b>P10</b>	<i>Delivery of Galunisertib to colorectal cancer cells by biosilica porous nanoparticles</i>	Chiara Tramontano	National Research Council of Naples, Italy
<b>P11</b>	<i>The LATS1 and LATS2 tumor suppressor kinases: a comprehensive multilayered MS-based analysis of their functional</i>	Bianca Kuhn	German Cancer Research Center (DKFZ), Germany

	<i>roles in breast cancer</i>		
<b>P12</b>	<i>Identification of resistance mechanisms and vulnerabilities to the mitotic inhibitor Rigosertib (ON-01910.Na)</i>	Ana Monfort-Vengut	Instituto de Investigaciones Biomédicas "Alberto Sols" CSIC, Spain
<b>P13</b>	<i>Inflammatory Macrophages Promote Basal-like Subtype Identity via Enhancer Reprogramming in Pancreatic Cancer</i>	Lukas Klein	University Medical Center Göttingen, Germany
<b>P14</b>	<i>Identification of genetic, epigenetic and cellular alterations responsible for distinct clinical outcomes of DNMT3A mutant AML</i>	Elisa Donato	German Cancer Research Center (DKFZ), Germany
<b>P15</b>	<i>Enhancement of anti-tumor T-cell immunity by means of an oral small molecule targeting the intracellular immune checkpoint MAP4K1</i>	Rafael Carretero Coca	German Cancer Research Center (DKFZ), Germany
<b>P16</b>	<i>A new label-free strategy to detect circulating tumor cells</i>	Maria Mangini	Institute of Biochemistry and Cell Biology, National Research Council, Italy
<b>P17</b>	<i>A BAP1 synonymous mutation results in exon skipping, loss of function and worse patient prognosis</i>	Samuel Peña-Llopis	German Cancer Consortium (DKTK) at University Hospital Essen, Germany
<b>P18</b>	<i>Integration of drug repurposing and pairwise screening unveils combinatorial therapies for mutant KRAS lung cancer</i>	Silvestre Vicent Cambra	Center for Applied Medical Research (CIMA-University of Navarra), Spain
<b>P19</b>	<i>Endomembranes promote chromosome missegregation by ensheathing misaligned chromosomes</i>	Nuria Ferrandiz	University of Warwick, UK
<b>P20</b>			
<b>P21</b>			
<b>P22</b>			
<b>P23</b>			

